Global pharmaceutical company Eli Lilly (NYSE:LLY) in Q4 CY2024, with sales up 44.7% year on year to $13.53 billion. The ...

2025 EPS Guidance: Expected between $22.50 and $24 on a non-GAAP basis. Eli Lilly and Co (NYSE:LLY) reported a 32% increase in full-year revenue for 2024, exceeding guidance by $4 billion.

Eli Lilly’s CEO Dave Ricks acknowledged the challenges in predicting ... Lilly’s revised 2024 guidance highlights the intense competition in the GLP-1RA market, dominated by Novo Nordisk ...

What will Eli Lilly do with all its cash from Mounjaro and Zepbound? What does CEO Dave Ricks think it would take for the company to reach a $1 trillion market capitalization? And how does Ricks ...

That’s how much Eli Lilly’s revenue grew in 2024, but it was still not as much as the company or investors expected, which had CEO David Ricks trying to assuage investors. Lilly on Tuesday ...

Shares of Eli Lilly & Co. were headed for their worst ... of growth for the quarter,” said Chief Executive David Ricks. Tomi Kilgore is MarketWatch's deputy investing and corporate news editor ...

Among some of the top news at the conference were M&A deal announcements by J&J, Eli Lilly and GSK. While J&J announced a big deal to acquire neuroscience company Intra-Cellular Therapies ...

SAN FRANCISCO — When Eli Lilly last year started offering lower ... are still prohibitive for many patients. CEO Dave Ricks said Lilly is now considering expanding the vial offering.

Eli Lilly expects its experimental weight loss pill, orforglipron, to be approved as soon as early next year, CEO David Ricks told Bloomberg. Eli Lilly and Novo Nordisk, which dominate the market ...

Good afternoon, everybody. I'm Chris Schott at JPMorgan and it's my pleasure to be hosting this fireside chat today with Dave Ricks, Chairman and CEO of Eli Lilly. It's been a tremendous few years ...